Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like ant... Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. Mehr anzeigen
Dr. Maltzman Brings Oncology and Autoimmune Experience in All Stages of Drug Development, from Early-Stage Research to Successful Regulatory Approvals and Commercialization Adicet Bio, Inc...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it...
First gamma delta CAR T cell therapy with the potential to address solid tumors entering clinical trials Preliminary Phase 1 clinical data expected in the first half of 2025 Adicet Bio, Inc...
Enrollment underway for lupus nephritis (LN) patients Preliminary clinical data in LN anticipated in 1H25 Initiation of patient enrollment in systemic lupus erythematosus (SLE), systemic...
-Data demonstrate characteristics essential for treatment of autoimmune diseases, including robust tissue homing and complete CD19+ B cell depletion in secondary lymphoid tissue -Results...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.1432 | -13.5094339623 | 1.06 | 1.06 | 0.8983 | 485310 | 0.97003453 | CS |
| 4 | -0.1232 | -11.8461538462 | 1.04 | 1.19 | 0.886 | 821380 | 0.9900106 | CS |
| 12 | -0.4632 | -33.5652173913 | 1.38 | 1.54 | 0.886 | 607496 | 1.16617789 | CS |
| 26 | -0.3832 | -29.4769230769 | 1.3 | 1.7 | 0.886 | 690381 | 1.28312297 | CS |
| 52 | -0.7032 | -43.4074074074 | 1.62 | 3.77 | 0.886 | 1036982 | 1.96237027 | CS |
| 156 | -14.5832 | -94.0851612903 | 15.5 | 21.87 | 0.886 | 718756 | 5.80419809 | CS |
| 260 | -14.0632 | -93.8798397864 | 14.98 | 21.87 | 0.886 | 601388 | 6.95383072 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
